Alkem Laboratories Ltd vs Bafna Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Alkem Laboratories Ltd is ₹ 5378 as of 04 May 09:39 . The P/E Ratio of Alkem Laboratories Ltd changed from 20.9 on March 2021 to 26.9 on March 2025 . This represents a CAGR of 5.18% over 5 yearsThe P/E Ratio of Bafna Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Alkem Laboratories Ltd changed from ₹ 33145 crore on March 2021 to ₹ 58347 crore on March 2025 . This represents a CAGR of 11.97% over 5 yearsThe Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Alkem Laboratories Ltd for the Dec '25 is ₹ 3879 crore as compare to the Sep '25 revenue of ₹ 4104 crore. This represent the decline of -5.48% The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Alkem Laboratories Ltd for the Dec '25 is ₹ 918.31 crore as compare to the Sep '25 ebitda of ₹ 1024 crore. This represent the decline of -10.36% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Alkem Laboratories Ltd changed from ₹ 550.24 crore to ₹ 653.53 crore over 7 quarters. This represents a CAGR of 10.33% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Alkem Laboratories Ltd changed from 21.28 % on March 2021 to 23.59 % on March 2025 . This represents a CAGR of 2.08% over 5 yearsThe Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Alkem Laboratories Ltd

Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations.
The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. Alkem Laboratories Limited was incorporated as a private limited company on August 8, 1973 in Patna and subsequently became a deemed public limited company on October 26, 1988.
Pursuant to Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of the Company was changed to 'Alkem Laboratories Limited' with effect from October 26, 1988.

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

FAQs for the comparison of Alkem Laboratories Ltd and Bafna Pharmaceuticals Ltd

Which company has a larger market capitalization, Alkem Laboratories Ltd or Bafna Pharmaceuticals Ltd?

Market cap of Alkem Laboratories Ltd is 64,613 Cr while Market cap of Bafna Pharmaceuticals Ltd is 321 Cr

What are the key factors driving the stock performance of Alkem Laboratories Ltd and Bafna Pharmaceuticals Ltd?

The stock performance of Alkem Laboratories Ltd and Bafna Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alkem Laboratories Ltd and Bafna Pharmaceuticals Ltd?

As of May 4, 2026, the Alkem Laboratories Ltd stock price is INR ₹5404.05. On the other hand, Bafna Pharmaceuticals Ltd stock price is INR ₹135.7.

How do dividend payouts of Alkem Laboratories Ltd and Bafna Pharmaceuticals Ltd compare?

To compare the dividend payouts of Alkem Laboratories Ltd and Bafna Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.